¼¼°èÀÇ ¼¾Æ®·² ·¦ ¼­ºñ½º/ÀÓ»ó½ÃÇè ½ÇÇè½Ç ¼­ºñ½º ½ÃÀå : »óº°, ¼­ºñ½º À¯Çüº°, Ä¡·á ºÐ¾ßº°, ¸ð´Þ¸®Æ¼º°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ¿¹Ãø(-2030³â)
Central Lab Services/Clinical Trial Lab Services Market by Phase (Phase I, II, III), Service Type (Safety Testing, Immunology), Therapeutic Area (Oncology), Modality (Small Molecules, Vaccine), End user (Pharma & CROs) & Region - Global Forecast to 2030
»óǰÄÚµå : 1684188
¸®¼­Ä¡»ç : MarketsandMarkets
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 311 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 7,162,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,650 £Ü 9,621,000
PDF (5-user License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,150 £Ü 11,792,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. (100% ÀÚȸ»ç´Â µ¿ÀÏ ±â¾÷À¸·Î °£Áֵ˴ϴÙ.) Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Àü ¼¼°è ¼¾Æ®·² ·¦ ¼­ºñ½º/ÀÓ»ó½ÃÇè ½ÇÇè½Ç ¼­ºñ½º ½ÃÀå ±Ô¸ð´Â 2025³â 59¾ï 7,000¸¸ ´Þ·¯¿¡¼­ 2030³â 81¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ 6.5%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¶»ç ¹üÀ§
Á¶»ç ´ë»ó ¿¬µµ 2024-2030³â
±âÁØ ¿¬µµ 2024³â
¿¹Ãø ±â°£ 2024-2030³â
°ËÅä ´ÜÀ§ ±Ý¾×(10¾ï ´Þ·¯)
ºÎ¹® »óº°, ¼­ºñ½º À¯Çüº°, Ä¡·á ºÐ¾ßº°, ¸ð´Þ¸®Æ¼º°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
´ë»ó Áö¿ª ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

ÀÌ·¯ÇÑ ¹è°æ¿¡´Â ½Å¾à°³¹ßÀÇ Ã¤¿ëÀÌ Áõ°¡Çϰí, ä¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, ÇコÄɾ ´ëÇÑ Á¤ºÎ º¸Á¶±Ý Áö¿øÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÓ»ó½ÃÇèÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ¿¡ µû¶ó Áß¾Ó¿¬±¸¼ÒÀÇ ÀÓ»ó ¼­ºñ½º ½ÃÇè¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÓ»ó½ÃÇè ¹æ¹ý°ú °ü·ÃµÈ ³ôÀº ºñ¿ëÀÌ ½ÃÀåÀÇ ÁÖ¿ä ¾ïÁ¦¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼÷·ÃµÈ ÀÇ·á Àü¹®°¡ÀÇ ºÎÁ·°ú ¼­ºñ½º¿¡ ´ëÇÑ Á¦ÇÑµÈ Áö½ÄÀº ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä °úÁ¦ÀÔ´Ï´Ù. ±×·¯³ª 2025-2030³â ¿¹Ãø ±â°£ µ¿¾È¿¡´Â ½ÃÀå ¼ºÀåÀ» À§ÇÑ È¯°æÀÌ Á¶¼ºµÇ°í ÀÖ½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î ¼¾Æ®·² ·¦ ¼­ºñ½º/ÀÓ»ó½ÃÇè ½ÇÇè½Ç ¼­ºñ½º ½ÃÀåÀº Á¦¾à ¹× ¹ÙÀÌ¿À Á¦¾à ±â¾÷, CROS, ÀÇ·á±â±â ±â¾÷, ±âŸ ÃÖÁ¾»ç¿ëÀÚ·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áß 2024³â ¼¾Æ®·² ·¦ ¼­ºñ½º/ÀÓ»ó½ÃÇè ½ÇÇè½Ç ¼­ºñ½º ½ÃÀå¿¡¼­ Á¦¾à ¹× ¹ÙÀÌ¿ÀÁ¦¾à ±â¾÷ÀÌ 61.8%·Î °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â Èñ±ÍÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ´ëºÎºÐÀÇ Á¦¾à»çµéÀº °íµµÀÇ ±â¼úÀ» Ȱ¿ëÇÏ¿© ÀÌ·¯ÇÑ ÁúȯÀÇ Ä¡·á¸¦ À§ÇØ ÀÓ»ó½ÃÇèÀ» ÁøÇàÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ´ëºÎºÐÀÇ ±â¾÷µéÀº ÀÌ·¯ÇÑ ¼­ºñ½º¸¦ ¼±È£Çϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ Áúº´ÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Àå±âÀûÀÎ Ä¡·áÀÇ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¼¾Æ®·² ·¦ ¼­ºñ½º/ÀÓ»ó½ÃÇè ½ÇÇè½Ç ¼­ºñ½º ½ÃÀåÀÇ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¼¾Æ®·² ·¦ ¼­ºñ½º/ÀÓ»ó½ÃÇè½Ç ¼­ºñ½º ½ÃÀåÀº Ä¡·á ºÐ¾ßº°·Î Á¾¾çÇÐ, °¨¿°ÇÐ, ½Å°æÇÐ, ½ÉÀåÇÐ, ±âŸ Ä¡·á ºÐ¾ß·Î ±¸ºÐµË´Ï´Ù. ¼¾Æ®·² ·¦ ¼­ºñ½º/ÀÓ»ó½ÃÇè ½ÇÇè½Ç ¼­ºñ½º ½ÃÀå¿¡¼­´Â ¾Ï ȯÀÚÀÇ Áõ°¡·Î ÀÎÇØ ¾Ï ºÐ¾ß°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¾Ï ºÐ¾ß ÀÓ»ó½ÃÇè¿¡¼­´Â ÀÓ»ó½ÃÇè¿¡¼­ »õ·Î¿î ¾Ï Ä¡·áÁ¦ÀÇ À¯È¿¼º°ú ¾ÈÀü¼ºÀ» Æò°¡Çϱâ À§ÇØ ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç, À¯Àüü °Ë»ç, Á¾¾ç ÇÁ·ÎÆÄÀϸµ µî ÃֽŠÁø´Ü °Ë»ç°¡ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹½À´Ï´Ù. ¼¾Æ®·² ·¦Àº ÀÌ·¯ÇÑ ¼­ºñ½º¸¦ Á¦°øÇÏ´Â µ¥ ÀÖ¾î Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, °Ë»ç°¡ ½ÇÇà °¡´ÉÇϰí, Àϰü¼º ÀÖ°í, ¿©·¯ ±â°ü¿¡¼­ ±ÔÁ¦ ±âÁØÀ» ÁؼöÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇÕ´Ï´Ù. Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó, ¾Ï ºÐ¾ß´Â Àü¹®ÀûÀÌ°í °íǰÁúÀÇ °Ë»ç½Ç °Ë»ç¿¡ ´ëÇÑ ¿ä±¸°¡ Ä¿Áö¸é¼­ ¼¾Æ®·² ·¦ ¼­ºñ½º ½ÃÀå¿¡¼­ °¡Àå Å©°í Áß¿äÇÑ ºÐ¾ß°¡ µÇ¾ú½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº ¼¾Æ®·² ·¦ ¼­ºñ½º/ÀÓ»ó½ÃÇè ½ÇÇè½Ç ¼­ºñ½º¿¡¼­ °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â Áö¿ª ½ÃÀåÀ̸ç, ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â Èñ±ÍÁúȯÀÇ À¯º´·ü Áõ°¡¿Í Áö¿ª ³» Àα¸ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡´Â ÀϺ», Áß±¹, Àεµ ¹× ±âŸ ±¹°¡°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ Áß Áß±¹Àº 2024³â ¼¾Æ®·² ·¦ ¼­ºñ½º/ÀÓ»ó½ÃÇè ½ÇÇè½Ç ¼­ºñ½º ½ÃÀå¿¡¼­ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â Á¦¾à ¹× »ý¸í°øÇÐ »ê¾÷ÀÇ ±Þ¼ÓÇÑ ¼ºÀå°ú ´õºÒ¾î ȯÀÚ ¼ö°¡ ¸¹°í Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. Çѱ¹Àº ÇコÄɾî ÀÎÇÁ¶óÀÇ ¹ßÀü, Àӻ󿬱¸¿¡ ´ëÇÑ ÅõÀÚ, ±ÔÁ¦ ȯ°æÀÇ °³¼±À¸·Î ÀÎÇØ ¼¼°è ÀÓ»ó½ÃÇèÀÇ ¸Å·ÂÀûÀÎ °ÅÁ¡ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ¼¾Æ®·² ·¦ ¼­ºñ½º/ÀÓ»ó½ÃÇè½Ç ¼­ºñ½º ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, »óº°, ¼­ºñ½º À¯Çüº°, Ä¡·á ºÐ¾ßº°, ¸ð´Þ¸®Æ¼º°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÀÔ ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ÁÖ¿ä ÀλçÀÌÆ®

Á¦5Àå ½ÃÀå °³¿ä

Á¦6Àå ¼¾Æ®·² ·¦ ¼­ºñ½º/ÀÓ»ó½ÃÇè ½ÇÇè½Ç ¼­ºñ½º ½ÃÀå, »óº°

Á¦7Àå ¼¾Æ®·² ·¦ ¼­ºñ½º/ÀÓ»ó½ÃÇè ½ÇÇè½Ç ¼­ºñ½º ½ÃÀå, ¼­ºñ½º À¯Çüº°

Á¦8Àå ¼¾Æ®·² ·¦ ¼­ºñ½º/ÀÓ»ó½ÃÇè ½ÇÇè½Ç ¼­ºñ½º ½ÃÀå, Ä¡·á ºÐ¾ßº°

Á¦9Àå ¼¾Æ®·² ·¦ ¼­ºñ½º/ÀÓ»ó½ÃÇè ½ÇÇè½Ç ¼­ºñ½º ½ÃÀå, ¸ð´Þ¸®Æ¼º°

Á¦10Àå ¼¾Æ®·² ·¦ ¼­ºñ½º/ÀÓ»ó½ÃÇè ½ÇÇè½Ç ¼­ºñ½º ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå ¼¾Æ®·² ·¦ ¼­ºñ½º/ÀÓ»ó½ÃÇè ½ÇÇè½Ç ¼­ºñ½º ½ÃÀå, Áö¿ªº°

Á¦12Àå °æÀï ±¸µµ

Á¦13Àå ±â¾÷ °³¿ä

Á¦14Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global Central lab services/clinical trial lab services market is projected to reach USD 8.18 billion by 2030 from USD 5.97 billion in 2025, at a CAGR of 6.5% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2024-2030
Units ConsideredValue (USD billion)
SegmentsPhase, Service Type, Therapeutic Area, Application,End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa

This is due to increasing adoption of drug discovery, as the adoption increases the demand for these services rises. Additionally, increasing government support to provide grants for healthcare is increasing, thus rising the number of clinical trials, consequently increasing the demand for the central lab clinical service trial. However, the high cost associated with the clinical trial methods are the major restraint to the market. Additionally, the shortage of trained healthcare professionals & limited knowledge about the services is major challenge for the market growth. But is creating a conducive environment for market expansion over the forecast period of 2025-2030.

"The pharmaceutical & biopharmaceutical companies segment of central lab services/clinical trial lab services market by end user to hold largest position forecast period."

Based on the end user, the central lab services/clinical trial lab services market is divided into pharmaceutical & biopharmaceutical companies, CROS, medical device companies, and other end users. Among these, in 2024 pharmaceutical & biopharmaceutical companie segment account for the largest market share of 61.8% in central lab services/clinical trial lab services market. This is due to the rising prevalence of rare disease. Majority of the pharmaceutical companies are conducting the clinical trials for the cure of such diseases via advanced technologies. Thus, majority of the companies prefer these services. Thus, as the prevalence of these diseases is increasing the need for long term treatment is rising, consequently increasing the demand for central lab services/clinical trial lab services market.

"The oncology segment accounts for the largest market share in central lab services/clinical trial lab services market."

Based on theraprutic area, the central lab services/clinical trial lab services market is segmented into oncology, infectious diseases, neurology, cardiology, and other therapeutic areas. The oncology segment holds for the largest market share in central lab services/clinical trial lab services market due to increasing number of cancer patients. Oncology clinical trials often require modern diagnostic testing, including biomarker testing, genomic testing, and tumor profiling, to assess the effectiveness and safety of new cancer therapies in clinical trials. Central labs are important in providing these services, ensuring that testing is viable, consistent, and compliant with regulatory standards across multiple sites. With the rising focus on precision medicine, the need for specialized and high-quality lab testing in oncology is significant, making the oncology segment the largest and most critical in the central lab services market.

"Asia Pacific is the fastest growing region of the central lab services/clinical trial lab services market by region."

The global central lab services/clinical trial lab services market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing regional market for entral lab services/clinical trial lab services and is estimated to grow at the highest CAGR during the forecast period. This is due to increasing prevalence of rare diseases and rising population across the region. Asia Pacific region includes Japan, China, India, and Rest of Asia Pacific. Among these, China accounts for the largest market share in central lab services/clinical trial lab services market in 2024. This is due to its rapid expansion of pharmaceutical and biotechnology industries, added with the with a large patient population and increasing demand for innovative treatments. The country's growing healthcare infrastructure, investment in clinical research, and supportive regulatory environment have made it an attractive hub for global clinical trials.

A breakdown of the primary participants referred to for this report is provided below:

Note 1: Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the central lab services/clinical trial lab services market are Thermo Fisher Scientific Inc. (US), IQVIA (US), ICON plc (Ireland), Labcorp (US), Quest Diagnostics (US), Charles River Laboratories (US), Medpace (US), Frontage lab (US), SGS Societe Generale de Surveillance SA (Switzerland), Eurofins Scientific (Luxembourg), and REPROCELL Inc. (Japan).

Research Coverage

This report studies the central lab services/clinical trial lab services market based on product, type, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE

7 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE

8 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA

9 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY

10 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER

11 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY REGION

12 COMPETITIVE LANDSCAPE

13 COMPANY PROFILES

14 APPENDIX

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â